These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6541581)

  • 1. Vindesine in the treatment of metastatic breast cancer.
    Hansen PV; Brincker H
    Eur J Cancer Clin Oncol; 1984 Oct; 20(10):1221-5. PubMed ID: 6541581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of vindesine in patients with metastatic breast cancer.
    Cobleigh MA; Williams SD; Einhorn LH
    Cancer Treat Rep; 1981; 65(7-8):659-63. PubMed ID: 7248983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion.
    Yap HY; Blumenschein GR; Bodey GP; Hortobagyi GN; Buzdar AU; DiStefano A
    Cancer Treat Rep; 1981; 65(9-10):775-9. PubMed ID: 7273012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vindesine for metastatic malignant melanoma. A phase II trial.
    Nelimark RA; Peterson BA; Vosika GJ; Conroy JA
    Am J Clin Oncol; 1983 Oct; 6(5):561-4. PubMed ID: 6613921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma.
    Yau JC; Yap YY; Buzdar AU; Hortobagyi GN; Bodey GP; Blumenschein GR
    Cancer; 1985 Jan; 55(2):337-40. PubMed ID: 3880657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of vindesine in patients with advanced breast cancer.
    Walker BK; Raich PC; Fontana J; Subramanian VP; Rogers JS; Knost JA; Denning B
    Cancer Treat Rep; 1982 Sep; 66(9):1729-32. PubMed ID: 6288237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vindesine in advanced renal cancer. A study of the EORTC Genito-urinary Tract Cancer Cooperative Group.
    Fosså SD; Denis L; van Oosterom AT; de Pauw M; Stoter G
    Eur J Cancer Clin Oncol; 1983 Apr; 19(4):473-5. PubMed ID: 6305668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology, clinical efficacy and adverse effects of vindesine sulfate, a new vinca alkaloid.
    Cersosimo RJ; Bromer R; Licciardello JT; Hong WK
    Pharmacotherapy; 1983; 3(5):259-74. PubMed ID: 6359081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous infusion vindesine in solid tumors.
    Bodey GP; Yap HY; Yap BS; Valdivieso M
    Cancer Treat Rev; 1980 Sep; 7 Suppl 1():39-45. PubMed ID: 7438120
    [No Abstract]   [Full Text] [Related]  

  • 10. A randomized study of continuous infusion vindesine versus vinblastine in adults with refractory metastatic sarcomas.
    Yap BS; Benjamin RS; Plager C; Burgess MA; Papadoupoulos N; Bodey GP
    Am J Clin Oncol; 1983 Apr; 6(2):235-8. PubMed ID: 6829497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vindesine in advanced breast cancer, lymphoma and melanoma. A Colorado Clinical Oncology Group study.
    DiBella NJ; Berris R; Garfield D; Fink K; Speer J; Sakamoto A
    Invest New Drugs; 1984; 2(3):323-8. PubMed ID: 6511238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine.
    Garewal HS; Brooks RJ; Jones SE; Miller TP
    J Clin Oncol; 1983 Dec; 1(12):772-5. PubMed ID: 6422004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vindesine and adriamycin in the therapy of metastatic breast cancer].
    Wander HE; Nagel GA
    Onkologie; 1982 Aug; 5 Suppl():5-7. PubMed ID: 6752792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors.
    Miller TP; Jones SE; Chester A
    Cancer Treat Rep; 1980; 64(8-9):1001-3. PubMed ID: 7448818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vindesine. A phase II trial in advanced breast cancer patients.
    Robins HI; Tormey DC; Skelley MJ; Falkson G; Crowley JJ; Ramirez G; Falkson H
    Cancer Clin Trials; 1981; 4(4):371-5. PubMed ID: 7318120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vindesine: phase II evaluation in colon cancer and description of its platelet stimulating activity.
    Pazdur R; Rossof AH; Chandra G; Bonomi PD; Slayton RE; Wolter J
    Cancer Chemother Pharmacol; 1982; 9(1):41-4. PubMed ID: 7139851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
    Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
    Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience.
    Bruno S; Puerto VL; Mickiewicz E; Hegg R; Texeira LC; Gaitan L; Martinez L; Fernandez O; Otero J; Kesselring G
    Am J Clin Oncol; 1995 Oct; 18(5):392-6. PubMed ID: 7572754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer.
    Ibrahim NK; Valero V; Theriault RL; Willey J; Walters RS; Buzdar AU; Booser DJ; Hortobagyi GN
    Am J Clin Oncol; 2000 Apr; 23(2):117-21. PubMed ID: 10776969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vindesine as a single agent and in combination with adriamycin in the treatment of metastatic breast carcinoma.
    Smith IE; Coombes RC; Evans BD; Ford HT; Gazet JC; Gordon C; McKinna JA; Powles TJ
    Eur J Cancer (1965); 1980; Suppl 1():271-3. PubMed ID: 7032939
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.